🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Adenocarcinoma of the Rectum

Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma NCT05752136Phase 31 site📍 Hangzhou Sir Run Run Shaw Hospital · Tests: Envafolimab A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer NCT06637462NA6 sites📍 Middletown📍 Montvale📍 Commack Memorial Sloan Kettering Cancer Center · Tests: Endoscopy Prospective Monocentric Study Evaluating the Circulating NK Cells Phenotype and the ImmunoScore® in Patients With Non Metastatic Rectal Cancer NCT06536127NA1 site📍 Avignon Institut Sainte Catherine · Tests: Blood samples Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors NCT04165772Phase 210 sites📍 Hartford📍 Miami📍 Basking Ridge Memorial Sloan Kettering Cancer Center · Tests: TSR-042 or Dostarlimab, capecitabine or 5-FU, Intensity Modulated Radiation Therapy (IMRT) Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal Cancer NCT06965166n/a1 site📍 Rochester Mayo Clinic · Tests: PCD-CT Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer NCT06328361NA13 sites📍 Tallinn📍 Tallinn📍 Tallinn Tampere University Hospital · Tests: Nonoperative surveillance mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC NCT06791512Phase 31 site📍 Guangzhou Jun Huang · Tests: mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody, mFOLFOX6 Interest of PET-MRI in the Evaluation of the Response After Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma NCT05772481n/a1 site📍 Strasbourg Centre Paul Strauss · Tests: PET-MRI Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal Adenocarcinoma NCT06402864Phase 311 sites📍 Avignon📍 Lyon📍 Lyon Gustave Roussy, Cancer Campus, Grand Paris · Tests: contact X-ray brachytherapy (CXB) SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC NCT07198165Phase 21 site📍 Shanghai Ruijin Hospital · Tests: PD-1 inhibitor based immunotherapy Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial NCT06850090Phase 31 site📍 Jinan Shandong Cancer Hospital and Institute · Tests: TAS-102, Capecitabine PET-imaging of Two Vartumabs in Patients With Solid Tumors NCT06645808EARLY Phase 11 site📍 Groningen Var2 Pharmaceuticals · Tests: 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo) NCT05663775Phase 21 site📍 Edmonton AHS Cancer Control Alberta · Tests: Mesalamine Exercise for Improving Long-course Chemoradiotherapy Efficacy in People With Locally Advanced Rectal Cancer NCT06276686EARLY Phase 11 site📍 Cottingham University of Hull · Tests: Supervised Vigorous intensity aerobic interval exercise A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies NCT05669430Phase 1, Phase 213 sites📍 Los Angeles📍 Denver📍 New Haven GV20 Therapeutics · Tests: GV20-0251, GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], GV20-0251 and Pembrolizumab [KEYTRUDA®] Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. NCT07407465Phase 228 sites📍 Lyon📍 Marseille📍 Paris Gruppo Oncologico del Nord-Ovest · Tests: Trastuzumab-Deruxtecan (T-DXd), Capecitabine, Bevacizumab Organ Preservation in Rectal Cancer: Contact X-ray Brachytherapy vs Extending the Waiting Interval and Local Excision NCT05772923NA7 sites📍 Nijmegen📍 Eindhoven📍 Amsterdam The Netherlands Cancer Institute · Tests: Contact x-ray brachytherapy, Local excision A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum NCT07811193Phase 2122 sites📍 Tucson📍 Ann Arbor📍 Detroit Vividion Therapeutics, Inc. · Tests: VVD-133214, Pembrolizumab Family Communications After Genetic Testing NCT07143487NA360 sites📍 Anchorage📍 Anchorage📍 Anchorage Alliance for Clinical Trials in Oncology · Tests: Biospecimen Collection, Genetic Testing, Communication Intervention, Survey Administration Beyond TME Origins NCT02292641NA4 sites📍 Oslo📍 Harrow📍 Oxford Imperial College London · Tests: New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pe… A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial) NCT07669220Phase 21 site📍 Guangzhou Sixth Affiliated Hospital, Sun Yat-sen University · Tests: Short-course Radiotherapy, SCRT, Toripalimab ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation NCT05059444n/a57 sites📍 Birmingham📍 Chandler📍 Hot Springs Guardant Health, Inc. · Tests: Guardant Reveal Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer NCT07372300Phase 31 site📍 Chiayi City Shih-Kai Hung · Tests: Hyperthermia FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery NCT06780787Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Balstilimab, Biospecimen Collection, Botensilimab, Capecitabine, Computed Tomography SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC NCT07549399Phase 31 site📍 Guangzhou Sixth Affiliated Hospital, Sun Yat-sen University · Tests: Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen, Cetuximab, Bevacizumab Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer NCT07200141Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: GTV 58.75 Gy/25 fractions(Simultaneous Integrated Boost), GTV 50 Gy/25 fractions(Simultaneous Integrated Boost), Concur… Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation NCT04668872n/a1 site📍 New York Memorial Sloan Kettering Cancer Center · Tests: Y90 TARE, PET/CT, PET/MRI Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy NCT06569368Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Metronidazole Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer NCT07448142Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Low-dose radiotherapy, Pucotenlimab, CAPEOX/XELOX Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer NCT02107105n/a1 site📍 Houston M.D. Anderson Cancer Center · Tests: Quality-of-Life Assessment, Questionnaire Administration
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy